Jan. 19, 2024 |
|
May. 14, 2024 |
|
jRCT2051230168 |
An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens |
|
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1 ) |
Watanabe Takanobu |
||
Gilead Sciences K.K. |
||
1-9-2, Marunouchi, Chiyoda-ku, Tokyo |
||
+81-3-6837-0740 |
||
ClinicalTrialGSJ@gilead.com |
||
Clinical Operations |
||
Gilead Sciences K.K. |
||
1-9-2, Marunouchi, Chiyoda-ku, Tokyo |
||
+81-3-6837-0740 |
||
JPClinicalOperations@gilead.com |
Recruiting |
Jan. 29, 2024 |
||
April. 08, 2024 | ||
671 | ||
Interventional |
||
randomized controlled trial |
||
open(masking not used) |
||
active control |
||
parallel assignment |
||
treatment purpose |
||
-If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL. |
||
-Prior use of, or exposure to, lenacapavir (LEN) |
||
18age old over | ||
No limit | ||
Both |
||
HIV-1-Infection |
||
-Experimental: Phase 3: BIC/LEN 75 mg/50 mg Fixed-dose Combination (FDC) |
||
Proportion of participants with HIV-1 RNA 50 or more copies/mL at Week 48 as determined by the US FDA-defined snapshot algorithm |
||
- Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48, Week 96 as determined by the US FDA-defined snapshot algorithm |
Gilead Sciences K.K. |
National Hospital Organization Osaka National Hospital IRB | |
2 Chome-1-14 Hoenzaka, Chuo Ward Osaka, Osaka, Osaka | |
Approval | |
No |
|
NCT05502341 | |
US/Australia/Canada/Dominican Republic/Puerto Rico/France/Germany/Italy/Korea/South Africa/Spain/Taiwan/United Kingdom/Argentina |